13 May 2024
13 May 2024
Under the deal, Novavax will receive a combination of cash and equity investments, including an upfront payment of $500m.
Highly potent active pharmaceutical ingredients (HPAPIs) are essential for chemotherapies and combination therapies. With specialised production facilities in great demand, what are the key challenges in HPAPI manufacturing?
RAPT is closing two Phase II trials for Rapt’s lead candidate, zelnecirnon, three months after the FDA placed a clinical hold on them.
As the debate over using tau levels to guide patient treatment persists, the landscape for Alzheimer’s diagnostics continues to move ahead.
The FDA has given an IND approval for WestGene’s mRNA therapeutic cancer vaccine as mRNA cancer vaccine development rises in popularity.
The positive Phase I/II data has supported a RMAT designation from the FDA and a PRIME designation by the EMA.
Maze is entitled to receive $150m in upfront payment from Shionogi.
Almost 12 months after the South American Summit, advancing pharma trade and raising disease response standards remains a priority.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
Give your business an edge with our leading industry insights.
